A Kinomic Approach to Identify Signaling Proteins Involved in Drug Resistance in GastroEnteroPancreatic Neuroendocrine Tumors Abstract #1739

Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) result in tumour growth stabilization, eventually followed by tumour progression. Thus, despite their original characteristics, NETs exhibit similar resistance features to treatments than other more common tumours.
Aim(s): We aim at identifying signaling partners responsible of acquired resistance to treatments in order to develop drug combinations to prevent resistance occurence.
Materials and methods: We engineered NETs cell lines, BON-1 and QGP-1, resistant to a chemotherapeutic agent, Oxaliplatin, and to an mTor inhibitor, Everolimus, by chronically exposing them to the drugs. We are using microarray-based kinomics to obtain highthroughput kinase activity profiles from drug sensitive vs resistant cells.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr David Romano

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Kosmas Daskalakis
#2091 Differential Signalling Pathways Drive Therapeutic Resistance in Neuroendocrine Tumors
Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) are insufficient due to poor knowledge of these tumours. Despite showing differentiated features, NETs often exhibit therapeutic resistance to common treatments similarly to other cancers. Although signalling abnormalities have been reported, molecular mechanisms responsible for this resistance phenomenon are yet to be understood.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr David Romano
Authors: Romano D, Gerard C, Poizat F, Niccoli P, ...
#2142 Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Introduction: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).
Conference: 15th Annual ENETS conference (2018)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: PhD Jennifer Wietzke
#2101 The Effect of Temozolomide on Pancreatic Neuroendocrine Tumors in Vitro and Role of MGMT and MMR System in Temozolomide Resistance
Introduction: Temozolomide (TMZ) has been suggested as a treatment option for patients with pancreatic neuroendocrine tumours (PNETs). The tumour response to TMZ has been linked to expression levels of O6-methylguanine-DNA methyltransferase (MGMT) and components of the mismatch repair (MMR) system.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Drs. Anela Blazevic
#2287 Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies
Introduction: The mTOR inhibitor Everolimus is approved for the treatment of PanNET and no predictive biomarker is available. mTOR is a central node controlling mitochondrial and aerobic glycolytic metabolisms.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Jerome Cros
Authors: Cros J, Bucau M, Raffenne J, Soukeur M, ...